BioMarin Pharmaceutical Inc. $BMRN Stock Position Raised by California State Teachers Retirement System

Key Points

• California State Teachers Retirement System increased its BioMarin stake by 5,328% in the second quarter, acquiring 11.45 million additional shares and bringing its ownership to 6.02%, valued at approximately $667.3 million. Institutional investors collectively own 98.71% of BMRN.
• BioMarin exceeded quarterly expectations, reporting $1.20 in earnings per share versus the $0.95 consensus and revenue of $989.7 million, up 20% year over year. The company’s FY 2026 EPS guidance is $4.90–$5.10.
• Analysts maintain a generally positive outlook, with the stock receiving a consensus rating of “Moderate Buy” and an average price target of $89.17, well above its reported price of $65.68.

California State Teachers Retirement System raised its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 5,328.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,662,523 shares of the biotechnology company's stock after acquiring an additional 11,447,664 shares during the period. California State Teachers Retirement System owned 6.02% of BioMarin Pharmaceutical worth $667,330,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. AlphaGrep UK Ltd bought a new position in BioMarin Pharmaceutical in the 2nd quarter worth about $335,000. Concurrent Investment Advisors LLC raised its holdings in shares of BioMarin Pharmaceutical by 87.2% during the second quarter. Concurrent Investment Advisors LLC now owns 14,106 shares of the biotechnology company's stock valued at $807,000 after buying an additional 6,572 shares during the last quarter. Secure Asset Management LLC raised its holdings in shares of BioMarin Pharmaceutical by 11.1% during the second quarter. Secure Asset Management LLC now owns 78,208 shares of the biotechnology company's stock valued at $4,475,000 after buying an additional 7,788 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of BioMarin Pharmaceutical during the second quarter worth approximately $5,258,000. Finally, Thornburg Investment Management Inc. boosted its position in shares of BioMarin Pharmaceutical by 305.9% during the second quarter. Thornburg Investment Management Inc. now owns 43,061 shares of the biotechnology company's stock worth $2,464,000 after buying an additional 32,453 shares during the period. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical Stock Performance

BioMarin Pharmaceutical stock opened at $65.68 on Monday. The company has a 50 day moving average price of $63.30 and a 200 day moving average price of $58.47. BioMarin Pharmaceutical Inc. has a 52 week low of $49.26 and a 52 week high of $70.98. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The firm has a market capitalization of $12.71 billion, a price-to-earnings ratio of 177.51, a P/E/G ratio of 0.47 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.95 by $0.25. The company had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The firm's quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Research analysts forecast that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on BMRN. Barclays raised their price objective on shares of BioMarin Pharmaceutical from $105.00 to $111.00 and gave the company an "overweight" rating in a research note on Monday, August 17th. Citigroup upped their target price on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a "buy" rating in a research report on Thursday, July 16th. HC Wainwright reaffirmed a "neutral" rating and set a $60.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday. Piper Sandler lifted their price target on BioMarin Pharmaceutical from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Tuesday, September 1st. Finally, UBS Group set a $88.00 price objective on BioMarin Pharmaceutical in a research note on Wednesday, August 26th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $89.17.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for rare and serious diseases. Founded in 1997 and headquartered in San Rafael, California, the company specializes in treatments for conditions that often have limited or no available therapeutic options, including inherited metabolic disorders, skeletal diseases, and certain bleeding disorders.

BioMarin's marketed products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for late-infantile neuronal ceroid lipofuscinosis type 2, Palynziq and Kuvan for phenylketonuria, and Voxzogo for achondroplasia in children with open growth plates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.